JNJ vs. TECH: Johnson & Johnson vs. Bio-Techne Stock Comparison

November 11, 2026

How do Johnson & Johnson (JNJ) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Johnson & Johnson (JNJ) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JNJ is classified in Pharmaceuticals while TECH is classified in Life Sciences Tools & Services.

Company profile comparison for Johnson & Johnson (JNJ) and Bio-Techne (TECH)
Profile Item	JNJ	TECH
Name	Johnson & Johnson	Bio-Techne Corp.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Life Sciences Tools & Services
GICS Sub-Industry	Pharmaceuticals	Life Sciences Tools & Services
Market Capitalization	664.95 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	January 2, 1962	February 9, 1989
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

JNJ

TECH

GSPC

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Johnson & Johnson (JNJ) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Johnson & Johnson (JNJ) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Johnson & Johnson (JNJ) and Bio-Techne (TECH)
Metric	JNJ	TECH
Total Return (1Y)	53.82%	27.56%
Total Return (3Y, Annualized)	27.51%	9.11%
Total Return (5Y, Annualized)	14.71%	-9.91%

Risk Profile

Drawdown History

JNJ

TECH

GSPC

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Johnson & Johnson (JNJ) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Johnson & Johnson (JNJ) and Bio-Techne (TECH)
Metric	JNJ	TECH
Volatility (1Y, Annualized)	21.23%	43.08%
Beta (5Y)	0.21	1.26
Max Drawdown (5Y)	-18.41%	-65.87%
Avg. Volume (3M)	6.93M	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

JNJ and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Johnson & Johnson (JNJ) and Bio-Techne (TECH)
Metric	JNJ	TECH
Sharpe Ratio (1Y)	2.33	0.54
Sortino Ratio (1Y)	3.66	0.82

Profitability

ROE (TTM)

Both Johnson & Johnson (JNJ) at 20.02% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max: 109.18%
JNJ: 20.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both Johnson & Johnson (JNJ) at 16.20% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.20%

Max: 18.05%
JNJ: 16.20%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Johnson & Johnson (JNJ) at 25.74% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.74%

Max: 83.12%
JNJ: 25.74%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Johnson & Johnson (JNJ) and Bio-Techne (TECH)
Metric	JNJ	TECH
ROE (TTM)	20.02%	8.33%
ROA (TTM)	8.46%	6.38%
Net Margin (TTM)	16.20%	14.00%
Operating Margin (TTM)	25.74%	12.21%
Gross Margin (TTM)	67.78%	66.23%

Growth

Revenue Growth

Both Johnson & Johnson (JNJ) at 6.05% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Johnson & Johnson (JNJ) at 90.50% and Bio-Techne (TECH) at 152.17% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Johnson & Johnson (JNJ) and Bio-Techne (TECH)
Metric	JNJ	TECH
Revenue Growth (YoY)	6.05%	-0.38%
Revenue Growth (3Y CAGR)	5.60%	2.25%
EPS Growth (YoY)	90.50%	152.17%
EPS Growth (3Y CAGR)	17.90%	-12.97%

Financial Strength

Current Ratio (MRQ)

Both Johnson & Johnson (JNJ) at 1.02 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.02

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
JNJ: 1.02
Min: 0.10

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Johnson & Johnson (JNJ) at 0.55 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.55

Max: 1.42
Q3: 0.65
JNJ: 0.55
Median: 0.15
Q1: 0.02
Min: 0.00

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Johnson & Johnson (JNJ) and Bio-Techne (TECH)
Metric	JNJ	TECH
Current Ratio (MRQ)	1.02	2.28
Debt / Equity (MRQ)	0.55	0.13
Net Debt / EBITDA	0.79	-0.20

Dividends

Dividend Yield (TTM)

Both Johnson & Johnson (JNJ) at 1.94% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

JNJ: 1.94%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Johnson & Johnson (JNJ) at 80.12% and Bio-Techne (TECH) at 27.59% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

80.12%

JNJ: 80.12%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Johnson & Johnson (JNJ) and Bio-Techne (TECH)
Metric	JNJ	TECH
Dividend Yield (TTM)	1.94%	0.44%
Dividend Payout Ratio (TTM)	80.12%	27.59%

Valuation

P/E Ratio (TTM)

Johnson & Johnson (JNJ) at 41.92 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.92

Max: 85.34
Q3: 43.46
JNJ: 41.92
Median: 26.69
Q1: 13.30
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Johnson & Johnson (JNJ) at 6.69 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 58.18
Q3: 25.77
Median: 7.30
JNJ: 6.69
Q1: 3.01
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Techne (TECH) at 5.28 is valued about in line with its industry on P/B ratio, while Johnson & Johnson (JNJ) at 8.16 carries an above-peer premium to book — JNJ is pricier on assets.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 13.53
JNJ: 8.16
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

Johnson & Johnson (JNJ) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Johnson & Johnson (JNJ) and Bio-Techne (TECH)
Metric	JNJ	TECH
P/E Ratio (TTM)	41.92	62.74
P/S Ratio (TTM)	6.69	9.31
P/B Ratio (MRQ)	8.16	5.28
Free Cash Flow Yield (TTM)	2.78%	2.39%